Isatuximab‐carfilzomib‐dexamethasone immediately after failing of the quadruplet Daratumumab‐bortezomib‐lenalidomide‐dexamethasone (Dara‐VRD): Striking response with no washout in a newly diagnosed multiple myeloma

Documenti analoghi

• Isatuximab‐carfilzomib‐dexamethasone immediately after failing of the quadruplet Daratumumab‐bortezomib‐lenalidomide‐dexamethasone (Dara‐VRD): Striking response with no washout in a newly diagnosed multiple myeloma
  di: Juan José Gil‐Fernández, et al.
  Pubblicazione: (2024-01-01)
• Daratumumab plus carfilzomib: An optimistic approach in relapsed/refractory multiple myeloma
  di: A P Dubey, et al.
  Pubblicazione: (2020-01-01)
• Monoclonal Antibodies: Leading Actors in the Relapsed/Refractory Multiple Myeloma Treatment
  di: Sonia Morè, et al.
  Pubblicazione: (2020-11-01)
• CD46 and CD59 inhibitors enhance complement-dependent cytotoxicity of anti-CD38 monoclonal antibodies daratumumab and isatuximab in multiple myeloma and other B-cell malignancy cells
  di: Hongjie Wang, et al.
  Pubblicazione: (2024-12-01)
• Infections in relapsed myeloma patients treated with isatuximab plus pomalidomide and dexamethasone during the COVID-19 pandemic: Initial results of a UK-wide real-world study
  di: Faouzi Djebbari, et al.
  Pubblicazione: (2022-12-01)